Health Trials

Advanced Solid Tumors With KRAS G12C Mutations

1

Review clinical trials related to Advanced Solid Tumors With KRAS G12C Mutations. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

Participants needed: 403
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Frontier Medicines CorporationUpdated: Mar 18, 2026Locations: 26
Eligibility criteria

Histologically or cytologically confirmed locally advanced unresectable or metas... [+4]

Leptomeningeal disease or carcinomatous meningitis [+4]

Read more